EFTA00299800.pdf

09/21/2018 10:18 From: Woodson C. Merrel l M Uebfax Page: 1/13 FAX COVER SHEET fo: Jeffrey Epstein / Company: Fax: Date: 9/21/2018 Subject: 9-14-18 LABCORP Lab Results Jeff From: Lisa Company: Woodson Merrell MD PLLC Phone: Pages w/cover: 13 Comments: EFTA00299800 09/21/2018 10:18 From: Woodson C. Merrell M Uebfax Page: 2/13 LabCorp Patient Report ,!me:, i:1 ",r-lbrU-2371-0 Convo! ID: F3 [143092 EPSTEIN, JEFFREY IS: ST NEW YORK NY 10021 Acct 31143092 Woodson Merrell 44E6AhS( New York NY 10065 Phone: Patient Details Specimen Details Physician Details D08:01/20/1953 Date toilette& 09/14/2018 1255 Local Ordering: W MERRELL Agely/m/d): 065/07/25 Date received: 09/15/2018 Referring: Gender: M 55N: Date entered: 09/15/2018 ID: MERRELL Patient ID: Date reported: 09/20/2018 0832 ET NPI: 1023153509 Rte: 68 General Comments & Additional Information Total Volume: Not Provided Ordered Items CSC WM Differential/Platelet; Comp. Metabolic Panel (14); Urinalysis, Routine; PE+Interp(Ftlx IFE),S; Lipid Panel; Iron and TIBC; Testostetone,Free+Weakly Sound; Vitamin 612 and Folate; FSH and LH; C-Reaclive Protein. Cardiac; Hemoglobin Ale; Prostate-Specific Ag, Serum; TSH; Vitamin D. 25-Hydroxy; Lipoprotein (a): IGF-1; ANA wiReflex; Homooyst(e)ine, Plasma; Prolactin; Thyroxine (T4) Free. Direct. S: Codisol; DHFA-Sulfate; Estradiol; Uric Acid; Phosphorus; LDH: GGT; Amylase; Ferritin. Serum: Insulin: Calcium, Ionized, Serum: Fibrinogen Activity; Magnesium, RBC; Request Problem Fasting: No TESTS RESULT FLAG -UNITS REFERENCE INTERVAL LAB. CSC With Differential/Platelet WBC RBC Hemoglobin Hematocrit MCV MCH MCHC RDW Platelets Neutrophils Lympha Monocytes Eos Satins Neutrophils (Absolute) 5.7 x1083/uL 3.4 - 10.8 01 4.90 x10E6/uL 4.14 - 5.80 01 14.7 g/dL 13.0 - 17.7 01 42.2 % 37.5 - 51.0 01 86 IL 79 - 97 01 30.0 pg 26.6 - 33.0 01 34.8 g/dL 31.5 - 35.7 01 14.6 t 12.3 - 15.4 01 242 xl0E3/u1 150 - 379 01 50 * Not Estab. 01 37 * Not Estab. 01 5 t Not Estab. 01 7 t Not Estab. 01 1 t Not Estab. 01 2.8 x10E3/uL 1.4 - 7.0 01 Lymphs (Absolute) 2.1 x10E3/uL 0.7 - 3.1 01 Monocytes(Absolute) 0.3 x10E3/uL 0.1 - 0.9 01 Eos (Absolute) 0.4 xl0E3/uL 0.0 - 0.4 01 Baso (Absolute) 0.0 xl0R3/uL 0.0 - 0.2 01 Immature Granulocytes 0 t Not Estab. 01 Immature Grans (Abs) 0.0 x10E3/uL 0.0 - 0.1 01 Comp. Metabolic Panel (14) Glucose 128 High mg/dL 65 - 99 01 Sample is lipemic. This may cause spurious increases in TBili, DBili, AST, ALT, and =X (if ordered). Clinical correlation indicated. Specimen received hemolyzed. Clinical correlation indicated. Datehmed:09/20/160032LT FINAL REPORT This document contains private and cu.t Jential heallf rotected by state and federal law. 01995-2018 Laboratory Corporation of America* Holdings If you have waived this document In error. please tall All lights Reserved • Enttrprhe Report Versiort 1.00 Page I of 6 EFTA00299801 09/21/2818 10:18 From: Woodson C. Merrell M Webfax Page: 3/13 IQ LaityOrp Patient Report Patiaat:EPSTEIN,MYRIEY DOB:01/20/1953 Patient ID: Control ID: F5831143092 Spocirnen ID: 257-4110-2371-0 Date collected: 09/14/2018 1255 LOW TESTS RESULT FLAG UNITS REFERENCE INTERVAL TAB BUN Creatinine eGFR If NonAfricn Am eGPR If Africn Am BUN/Creatinine Ratio Sodium Potassium 4.2 mmol/L 3.5 - 5.2 01 Sample is lipemic. This may cause spurious increases in TBili, DBili, AST, ALT, and UIBC (if ordered). Clinical correlation indicated. Specimen received hemolyzed. Clinical correlation indicated. Chloride 102 Carbon Dioxide, Total 20 Calcium 9.4 Protein, Total 6.7 Albumin 4.3 Globulin, Total 2.4 A/G Ratio 1.8 Bilirubin, Total 0.3 Alkaline Phosphates. 71 AST (SOOT) 26 IU/L The specimen was lipemic. The lipemia was cleared by ultracentrifugation before testing. However HDL, direct LDL, cholesterol and triglyceride (if ordered) were performed prior to ultracentrifugation. ALT (SGPT) 37 ItY/L 0 22 mg/dL 8 - 27 0.96 mg/dL 0.76 - 1.27 01 83 mL/min/1.73 >59 95 mL/min/1.73 >59 23 10 - 24 138 mmol/L 134 - 144 01 01 mmol/L mmol/L mg/dL g/dL g/dL g/dL mg/dL IU/L Urinalysis, Routine Urinalysis Gross Exam Specific Gravity pH Urine-Color Appearance NEC Esterase Protein Glucose Ketones Occult Blood Bilirubin Urebilinogen,Semi-On Nitrite, Urine Microscopic Examination Microscopic follows PE+Interp(Rfx IFE),S 1.027 5.5 Yellow Clear Negative Negative Negative Negative Negative Negative 0.2 Negative if indicated. 96 - 106 01 20 - 29 01 8.6 - 10.2 01 6.0 - 8.5 01 3.6 - 4.8 01 1.5 - 4.5 1.2 - 2.2 0.0 - 1.2 01 39 - 117 01 0 - 40 01 44 01 01 1.005 - 1.030 01 5.0 - 7.5 01 Yellow 01 Clear 01 Negative 01 Negative/Trace 01 Negative 01 Negative 01 Negative 01 Negative 01 EU/dL 0.2 - 1.0 01 Negative 01 01 Date Issued. 09120,18 0832 ET FINAL REPORT This document contains Private and conSiental health information tected by state and federal law. If you have receved this document in error. please cal Page? of 6 O 995-2018 Laboratory Coiporation of Americas Holdings Al Rights Reserved - fritorodse Reedit Ver3$OO: 1.00 EFTA00299802 09/21/2018 10:18 From: Woodson C. Merrell M Webfax Page: 4/13 LabCorp Patient Report Patient: EPSTEIN, HI FREY DOLS:01/20/1953 Patient ID: Control ID: F51B1143092 Specimen ID: 257-480-2371D Data collected: 09/14/2018 1255 Local TESTS RESULT FLAG UNITS REFERENCE INTERVAL LAB Albumin Alpha-1-Globulin Alpha-2-Globulin Beta Globulin Gamma Globulin M-Spike Globulin, Total A/G Ratio Please note: Protein electrophoresis scan will follow via computer, mail, or courier delivery. Interpretation(See Below) The SPE pattern appears essentially unremarkable. Evidence of monoclonal protein is not apparent. PDF 4.0 0.1 0.8 0.9 0.9 Not Observed 2.7 1.5 g/dL 2.9 - 4.4 g/dL 0.0 - 0.4 g/dL 0.4 - 1.0 g/dL 0.7 - 1.3 g/dL 0.4 - 1.8 g/dL Not Observed g/dL 2.2 - 3.9 0.7 - 1.7 Lipid Panel Cholesterol, Total 234 High mg/dL Tr1slycerides 1714 Alert mg/dL Results confirmed on dilution. HDL Cholesterol VLDL Cholesterol Cal 19 Low mg/dL mg/dL 01 01 01 01 01 01 01 01 01 100 - 199 01 0 - 149 01 >39 01 5 - 40 The calculation for the VLDL cholesterol is not valid when triglyceride level is >400 mg/dL. LDL Cholesterol Cale mg/dL 0 - 99 Triglyceride result indicated is too high for an accurate LDL cholesterol estimation. Iron and TIBC Iron Bind.Cap.(TIBC) 320 ug/dL 250 - 450 UIBC 252 ug/dL 111 - 343 01 Iron 68 ug/dL 38 - 169 01 Iron Saturation 21 t 15 - 55 Testosterone,Free+Weakly Bound Testosterone, Serum 140 Low ng/dL 264 - 916 01 Adult male reference interval is based on a population of healthy nonobese males (HM/ <30) between 19 and 39 years old. Travison, et.al. /CHM 2017,102;1161-1173. PMID: 28324103. Testost., V Free,Weakly Bound 9.0 - 46.0 02 Test Not Performed. Specimen is lipemic. Testost., F+W Bound 40.0 - 250.0 Unable to calculate result since non-numeric result obtained for component test. Vitamin B12 and Folate oatossued:o9nwisone FINAL REPORT Thisdocument contains private and confidential peak °woad by stele end federal law. If you have received this document in error, please tel Page 3 016 01995.2018 Iahoratoryfonsoretion of America, Hoe:lines Al nights Reserved -Enterprise Repon Version 101 EFTA00299803 09/21/2018 10:18 From: Woodson C. Merrell M Uebfax Page: 5/13 LabCorp Patient Report Patient: EPSTEIN, JEFFREY DOB: 01/20/1953 Patient ID: Cmitmlitkig01143092 Specimen ID: 257-480-23/1-0 Date collected: 09/14/2018 1255 Local TESTS RFEULT FLAG UNITS REFERENCE INTERVAL LAB Vitamin B12 Folate (Folic Acid), Serum Note: A serum folate concentration of less than 3.1 ng/mL is considered to represent clinical deficiency. FSH and LH LH FSH C-Reactive Protein, Cardiac 463 4.4 pg/mL ng/mL 232 - 1245 >3.0 01 01 01 3.7 mIU/mL 1.7 - 8.6 01 4.4 mIU/mL 1.5 - 12.4 01 1.56 mg/L 0.00 - 3.00 01 Relative Risk for Future Cardiovascular Event Low <1.00 Average 1.00 - 3.00 High >3.00 Hemoglobin Ale Hemoglobin Aic 5.5 § 4.6 - 5.6 01 Please Note: Prediabetes: 5.7 - 6.4 Diabetes: >6.4 Glycemic control for adults with diabetes: <7.0 01 Prostate-Specific Ag, Serum Prostate Specific Ag, Serum 0.7 ng/mL 0.0 - 4.0 01 Roche ECLIA methodology. According to the American Urological Association, Serum PSA should decrease and remain at undetectable levels after radical prostatectomy. The AUA defines biochemical recurrence as an initial PSA value 0.2 ng/mL or greater followed by a subsequent confirmatory PSA value 0.2 ng/mL or greater. Values obtained with different assay methods or kits cannot be used interchangeably. Results cannot be interpreted as absolute evidence of the presence or absence of malignant disease. TSH 1.290 uIU/mL 0.450 - 4.500 01 Vitamin D, 25-Hydroxy 20.2 Low ng/mL 30.0 - 100.0 01 Vitamin D deficiency has been defined by the Institute of Medicine and an Endocrine Society practice guideline as a level of serum 25-OH vitamin D less than 20 ng/mL (1,2). The Endocrine Society went on to further define vitamin D insufficiency as a level between 21 and 29 ng/mL (2). 1. IOM (Institute of Medicine). 2010. Dietary reference intakes for calcium and D. Washington DC: The National Academies Press. 2. Holick MP, Hinkley NC, Bischoff-Ferrari HA, et al. Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. JCEM. 2011 Jul; 96(7):1911-30. Date Issued: 09/20/180832 LT FINAL REPORT This document contains private and con9dentill hat. f 0:feted by stete and federal law. II you have received this document in error, please Page 406 0 1995-2018 Laboratory Corporation of America* Haling, All Rights Relieved • Entir9rIlle Neon Vermeer 1.00 EFTA00299804 09/21/2018 10:18 From: Woodson C. Merrell M Uebfax Page: 6/13 LfaliCorp Patient: EPSTEIN, JEEFREY DOB:01/20/1953 Patient Report Patient ID: Contra ID: F6831143092 Specimen ID: 257-480-1371-0 Date collected: 09/14/2018 1255 Local TESTS RESULT FLAG UNITS REFERENCE INTERVAL ISR Lipoprotein (a) 20 nmol/L <75 Note: Values greater than or equal to 75 nmol/L may indicate an independent risk factor for CHD, but must be evaluated with caution when applied to non-Caucasian populations due to the influence of genetic factors on Lp(a) across ethnicities. I0E-1 Insulin-Like Growth Factor I 137 ng/na, 49 - 188 02 ANA w/Reflex ANA Direct Negative Negative 01 Homocyst(e)ine, Plasma 14.9 umol/L 0.0 - 15.0 01 Prolactin 3.9 Low ng/ntL 4.0 - 15.2 01 Thyroxine (T4) Free, Direct, S T4,Free(Direct) 1.05 ng/dL 0.82 - 1.77 01 Cortisol 3.7 ug/dL 01 Cortisol AM 6.2 - 19.4 Cortisol PM 2.3 - 11.9 DEKA-Sulfate Estradiol Roche ECLIA methodology 181.8 ug/dL 30.9 - 295.6 02 28.3 pg/mL 7.6 - 42.6 01 Uric Acid Uric Acid 6.8 mg/dL 3.7 - 8.6 01 Please Note: 01 Therapeutic target for gout patients: <6.0 Phosphorus 3.6 mg/dL 2.5 - 4.5 01 LDH 213 IU/L 121 - 224 01 GGT 25 IU/L 0 - 65 01 Amylase 37 U/L 31 - 124 01 Ferritin, Serum 104 ng/mL 30 - 400 01 Insulin 47.2 High oIli/mI 2.6 - 24.9 01 Date Issued. 09120/18 0837 ET FINAL REPORT Thh doawrent contains private end ccnficlential heat otected by state and federal law. If you have tecelved IN, document in error, plea. call Page 5 of 6 1995-2018 LaboratoryCorporation of Ameticao holdings All lights noatived Enteeprhe Report Venlorc 1.00 EFTA00299805 09/21/2018 10:18 From:SOIS Woodson C. Merrel l M Uebfax Page: 7/13 RLabCorp Patient Report Patient: EPSTEIN, JEFFREY D0S:01/20/1953 PatlientIM Control ID:15831143092 Specimen ID: 257-48C-23710 Date collected: 09/114,2018 1255 Local TESTS RESULT FLAG UNITS REFERENCE INTERVAL LAB Calcium, Ionized, Serum 5.3 mg/dL 4.5 -- 5.6 01 Fibrinogen Activity 330 mg/dL 193 - 507 01 Specimen was ultracentrifuged before testing to remove extreme lipemia. Results should be interpreted with caution. Magnesium, RBC 5.4 mg/dL 4.2 - 6.8 02 Plasma NOT separated from cells; may falsely decrease RBC Magnesium levels. Request Problem Test Not Performed. Specimen is lipemic. TEST: 143257 Testost., % Pree+Weakly Bound Panel: 143255 02 01 RN LabCorp Raritan 69 First Avenue, Raritan, NJ 08889-1800 02 BN LabCorp Burlington 1447 York Court, Burlington, NC 27215-3361 For inquiries. the physician may contact Branch: Lab: Dir. Nautili B Reyes, MD Dir. William F Hancock. MD 1 Date Issued; 09120/180832 ET FINAL REPORT This document contains privateandconfidential health Inforrnaton tested by state and federal law. If you have received this document in era, pleats call Page 6 of 6 o 1995.2018 Laboratory Corporation of Amerce° Holdings All Monts Reserved • Enteepnte Report Venion, l.00 EFTA00299806 09/21/2818 18:18 From: iliddeigliWoodson C. Merrell M Uebfax Page: 8/13 Laboratory Corporation of America Special Chemistry Department Raritan New Jersey Serum Protein Electrophoresis Serum Proteins PE Gel T44577 Sample 32 09/17/2018 15:43:01:31 Accession Number Patient Name Total Protein Patient ID Birthdate Account No./Name 257480237106 EPSTEIN, JEFFREY 6.7 1/20/1953 31143092-Woodson Merrell Physician ID Account Address 1 Account Address 2 Account Addross 3 44 E 67th St New York, NY 10065 IIInh 11111]11111 257480237106 Fenton % gid I Range Atom& 60.3 4.0 2.9 to 4 . 4 Alpha.1 2.0 0.1 0.0 to 0 . 4 Alpha•2 11.7 0.8 0.4 to 1 . 0 Bea 13.3 0.9 0.7 to 1 . 3 Gamma 12.7 0.9 0.4 to 1 . 8 Twal 6.7 6.0 to 8.5 The SPE pattern appears essentially unremarkable. Evidence of monoclonal protein is not apparent. EFTA00299807 09/21/2618 10:18 From: Woodson C. Merrell M Uebfax Page: 9/1j "WI M P Specimen ID: 257-480-22300 Control ID: F4931143092 Patient Report EPSTEIN, JEFFREY 9E 71STST NEW YORK NY 10021 Acct d: 31143092 Woodson Merrell 44 E 67th St New York NY 10065 Phone: Rte: 68 Patient Details Specimen Decals Physician Details DOB: 01/2O/1953 Dam coRomed: 09/14/2018 1255 Local Ordering: Vd MERRELL AgeNSINdt %SAMS Date mollified: 09/152018 Referring: Conan: M 55N: Date entered: 09/15/2018 ID: Patient 0: E012053 Ono omens* 09/19/2018 0610 ET NPI: 1023153509 Ordered Items Vitamin 86. Plasma TESTS Vitamin B6, Vitamin B6 Disclaimer: This test was developed and its performance characteristics determined by LabCorp. It has not been cleared or approved by the Food and Drug Administration. RES12:7 FLAG UNITS REFERENCE INTERVAL LAE Plasma 7.2 ug/L 5.3 - 46.7 01 01 I 01 BN LabCorp Burlington 1447 York Court. Burlington, NC 27215-3361 For inquiries, the physician may contact Branch: Lab: DirWillarnFHancock.MD Date ISSued 09/21/18 0838 LT ANAL REPORT This document contains private and confdential host, informatIon proleceed by state and federM taw. If you hoe oceNed th)C ~nit in 'Mr , MdAeaw cat Page 1011 O 1945-2018 tabstatery Corporation of America* Flokengs Al Rights Reserved • Ent/toast Reran Yenta& 1.00 EFTA00299808 09/21/2818 10:18 From: Woodson C. Merrell M Uebfax Page: 10/13 OLabeforp Specimen ID: 257-480-2232-0 Control ID: F SA31143092 Patient Report EPSTEIN, JEFFREY Patient Details DOR:01/20/1953 Agety/m/d): 065/07/25 Gender M SSN: P.sticut tO. Specimen Details Date collected: 09/14/2018 Date received: 09/15/2018 Date entered: 09/15/2018 one reamed: miasma General Comments & Additional Information Total Volume: N0t Provided Ordered Items CaaPTH Intact Acct a: 31143092 Phone: Rte: 68 Woodson Merrell 44 E 67th St New York NY 10065 111111111.111111IIIIIIIIIIIIIIIIII'llIllalll'IIIIIIIIIIIIIIIIIII 1255 Local WPM tl Fasting: No Physician Details Ordering: Referring: ID: MERRELL NPI: TESTS RESULT FLAG UNITS REFERENCE INTERVAL LAB Ca+ PIE Intact Calcium Specimen received hemolyzed. C PTE, Intact Intact PTH 9.5 Interpretation mg/dL 8.6 - 10.2 cal correlation indicated. High Normal Primary Hyperparathyroidism Secondary Hyperparathyroidism Non-Parathyroid Hypercalcemia Hypoparathyroidism Non-Parathyroid Hypocalcemia In/mL 15 - 65 Intact PTH (pg/mL) Calcium (mg/dL) 15 - 65 8.6 - 10.2 >65 >10.2 >65 <10.2 <65 >10.2 <15 < 8.6 15 - 65 e 8.6 01 01 01 01 RN labCorp Raritan 69 First Avenue Raritan NJ 08869-1800 Dr: Aracel B Reyes. MO For Inquiries, the physician may contact Brandi: Lab: Daze Issued: 09/17!180916 ET FINAL REPORT 11-in document contains private and confickinitiai health Wombat:on tectied by state and federal law. If you have mewed :his document it error, please call Page 1 of 1 O1995-20Th Laboratory Colporaoon of ArnencasHoldIngs MI Rights Reserved Enterprise born Will= 140 EFTA00299809 09/21/2018 10:18 From: Woodson C. Merrel l M Uehfax Page: 11/13 Pir,Labrporp Specimen ID: 257480,2715-0 Control ID: END31143092 Patient Report EPSTEIN,JEFFREY 9E715TST NEW YORKNY 10021 Patient Details DOB:01/20/1953 Age(y/m/d): 065/07/25 Gender: M SSN: Patient ID: Acct a: 31 143092 Phone: Rte 68 Woodson Merrell 44 E 67th St New York NY 10065 tuhhhhlPdurPhrllllllllhlhPnhrllhhPPllllrllltllllll Specimen Details Physician Details Date collected: 09/14/2018 1255 Local Otclerniri ,,', MI HP II Date received: 09/15/2018 Refer, ing. Date entered: 09/15/2018 ID: Date reported 09/18/2018 0610 ET r4 of: 'C23:53509 General Comments A Additional Information Total Volume: Not Provided Ordered Items Chlamydia/GC AmplIkation. Panel 083935; HCV Ab wlRflx to Venficaton: RPR, Rix On RPR/Confirm TP Fasting: No TESTS RESULT FLAG UNITS REFERENCE INTERVAL • "LAB Chlamydia/GC Amplification Chlamydia trachomatis, NAA Neisseria gonorrhoeae, NAA Negative Negative Panel 083935 HIV Screen 4th Generation wRfx Non Reactive HCV Ab w/Rflx to Verification HCV Ab <0.1 Comment: Negative 01 Negative 01 Non Reactive 01 s/co ratio 0.0 0.9 01 Non reactive HCV antibody screen is consistent with no HCV infection, unless recent infection is suspected or other evidence exists to indicate HCV infection. 01 RPR, Rfx Qn RPR/Confirm TP RPR Non Reactive Non Reactive 01 01 RN LabCorp Raritan Dir: Aracek B Reyes. MO 69 First Avenue, Raritan, NJ 08869-1800 For Inquiries, the physician may coning Branch: Lab: Date Issued: 09/18/181053 ET FINAL REPORT This Occument contains pitate and coorticiernial health information blood by state andtederal if you have received this document in err,. please cal Page I el I iggS-2018 Latc,r atm)/ Corpnretion of Arft-1, '.Cei H0idlfrip All R Hight Rewrted Enterprise Ripon Version 1O0 EFTA00299810 09/21/2018 10:18 From: Woodson C. Merrel l M Uebfax Page: 12/13 Patient Report Specimen lb: : )7-480-2542-0 Control iD: P.../:31143092 EPSTEIN, JEFFREY 9 E 71ST ST NEW YORK N'T I i Patient Details DOB:01/20/1953 Age ly/mId):065/07/25 Gender: M SSN: Patient ID: Acct #: 31143092 Woodson Merrell 44 E 67th St New York NY 10065 Specimen Details Date collected: 09/14/2018 1255 Local Date received: 09/15/2018 Date entered: 09/15/2018 Date reported: 09/18/2018 0823 ET General Comments & Additional Information Total Volume: Not Provided Ordered Items Inc, Whole Blood Fasting: No Phone: Physician Details Ordering: W mERPEL1 Referring: ID: MERRELL NPR 1023153509 RN: 68 TESTS RISPLT Lplaa UNITS REFERENCE INTERVAL LAB Zinc, Whole Blood 01 BN LabCorp Burlington 1447 York Coun Burlington, NC 27215-3381 For inquiries, me physician may contact Branch: Lab: Dir. William F I lancock. MD Date Issued: 09/18.i81053 ET FINAL REPORT This docurnem contains private and confidential health • t' n tected bystale and federal law d you have °Keyed thn document in error, *ate 49 Page I of t 1995-2015 taboiatoryCorporalon of Arrieika•Holdinps All nights Reatived - Imerestisii Bataan WNW. 1.00 EFTA00299811 09/21/2818 10:18 From: Woodson C. Merrell M Wehfax Page: 1J/li Labegorp Patient Report Specimen ID: 257.480-2300-O Control 1D: 25648023000 EPSTEIN, JEFFREY 9 EAST 71 STREET NYC NY 10021 Acct M:31143092 Woodson Merrell 44 E 67th St New York NY 10065 Phone: Patient Details Specimen Details Physician Details D08:01/20/1953 Date colter:tech 09/14/2018 1255 Local Ordering: W MERRELL Age(y/m/d):065/07f25 Date received: 09/15/2018 Referring: Gender: M SSN: Date entered: 09/15/2018 ID: MEPAELL Patient ID: Date reportect 09/19/2018 1011 ET NPt 1023153509 Ordered Items Heavy Metals Profile II, Blood Rte 68 TESTS RESULT FLAG UNITS REFERENCE INTERVAL LAB Heavy Metals Profile II, Blood Lead, Blood 1 Blood Lead Collection Method: Venous Testing performed by Inductively coup Arsenic, Blood 8 Mercury, Blood Cadmium, Blood None Detected ug/dr.. 0 - 4 led plasma/Mass Spectrometry. Environmental Exposure: WHO Recommendation <20 Occupational Exposure: OSHA Lead Std 40 SRI 30 Detection Limit ug/L 2 - 23 Detection Limit m 1 2.1 ug/L 0.0 - 14.9 01 Environmental Exposure: <15.0 Occupational Exposure: BEI - Inorganic Mercury: 15.0 Detection Limit 1.0 ug/L 0.0 - 1.2 Environmental Exposure: Nonsmokers 0.3 - 1.2 Smokers 0.6 - 3.9 Occupational Exposure: OSHA Cadmium Std 5.0 BEI 5.0 Detection Limit m 0.5 01 01 01 01 BN LabCorp Burlbaton 1447 Yak Court, Burlington, NC 27215-3361 Di: WNW F Hancodt MD For Inceiries, the physician may contacA Branch: Lab: Date Issued: 0921/' 8 0838 ET FINAL REPORT This document contains private and confidential health information erred by state and federal law. f yeti hare monied this document in inter, please cal Page 1 of 01995-2018 Laboratory Corporation of Ametkaa Holdings Al RIghti Pawns/ -Enterprise itesaatt Venion: 1.00 EFTA00299812